Osteoporosis Drugs Market Observes tremendous growth during the Forecast period 2020-2027

 

Osteoporosis Drugs Market

Osteoporosis is defined by the micro-architectural degradation of bone tissue, which results in reduced bone mass and bone fragility, particularly in elderly people. Women are more susceptible to the illness than males, especially after menopause, when bone loss is hastened owing to decreased oestrogen, which protects the bones.

Osteoporosis is a medical disorder that affects people and is characterised by decreased bone density and quality. Furthermore, with this medical condition, the bones become porous, making them more weak and susceptible to fractures. The disorder is caused by an excessive amount of the hormone parathyroid. The disease might result in serious fractures, which can be harmful to the patient's health. As a result, the illness necessitates therapy, which involves the administration of osteoporosis Drugs. Bisphosphonates, selective oestrogen inhibitors modulator (SERM), parathyroid hormone treatment, calcitonin, and RANK ligand inhibitors are some of the Drugs on the market. These Drugs are given to patients by a variety of methods in the body, including orally and intravenously.

According to Coherent Market Insights, The global and China Osteoporosis Drugs Market was valued at US$ 12.7 Bn in 2019 and is forecast to reach a value of US$ 17.1 Bn by 2027 at a CAGR of 3.8% between 2020 and 2027.

The rise in the incidence of osteoporosis is a significant factor driving the growth of the osteoporosis Drugs market. Other factors driving the growth of the osteoporosis Drugs market include an increase in the global elderly population and the global adoption of a sedentary lifestyle. However, the market for osteoporosis Drugs is hampered by side effects and the time-consuming drug approval procedure. High development potential in developing economies, on the other hand, is likely to provide attractive prospects during the projection period.

The problem of osteoporosis is being addressed by major organisations. The International Osteoporosis Foundation, for example, teamed with Amgen and UCB, a worldwide biopharmaceutical business, in June 2020, in conjunction with the University of Oxford, to promote its Capture the Fracture campaign, which seeks to reduce hip and vertebral fractures by 25% by 2025. The market is likely to rise with the approval and introduction of AI-based solutions to forecast osteoporosis. For example, Zebra Medical Vision gained FDA 510(k) clearance for its Vertebral Compression Fractures product in May 2020. This tool automatically recognises evidence suggestive of compression fractures, allowing doctors to place patients at risk of osteoporosis in treatment pathways.

For companies in the worldwide and Chinese osteoporosis Drugs markets, R&D in innovative treatments is projected to provide attractive development prospects. For example, in June 2020, researchers from CHA University's School of Medicine in South Korea reported that tauroursodeoxycholic acid, a hydrophilic bile acid approved by the US Food and Drug Administration for the treatment of chronic cholestatic liver disease, may have a beneficial effect on bones and could be used to prevent and treat osteoporosis. Furthermore, an increase in the number of smokers is projected to help the market develop. According to the World Health Organization, 1.337 billion people globally smoked tobacco in 2018.

Major players operating in the global and China osteoporosis drugs market include, Merck & Co., Eli Lilly, Procter & Gamble, Enzo Biochem, Inc., Sanofi-Aventis, Novartis, Wyeth, Roche, GlaxoSmithKline, UCB, Amgen, BeiGene Co., Ltd., Bone Biologics, Teijin Pharma Limited, JHL Biotech Inc., Keros Therapeutics, and Taro Pharmaceuticals Inc.